Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Southwest Airlines Co (LUV) vs Nuvalent Inc (NUVL) Price & Performance

Southwest Airlines CoTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Southwest Airlines Co vs Nuvalent Inc — how do they compare? Southwest Airlines Co trades at $48.82 (market cap $23.63B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Southwest Airlines Co is far larger — about 2.4× Nuvalent Inc's market cap, and Southwest Airlines Co pays a 1.49% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

LUVNUVL
Market Cap
$23.63B$9.81B
Sector
IndustrialsTechnology
52-Week High
$54.80$123.96
52-Week Low
$29.06$72.16
Enterprise Value
$26.70B$8.52B
Dividend Yield
1.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Southwest Airlines Co

Southwest Airlines (LUV) trades at $48.28, up 0.42% today, with a neutral technical signal and mixed earnings history. Recent Q1 2026 EPS missed expectations, but Q4 2025 and Q3 2025 beat. Financials show modest revenue growth to $28.06B in 2025, but net income margin is thin at 2.83%. Analyst consensus is mixed with 42% buy, 47% hold, and 11% sell ratings, and a $52.47 price target implies potential upside. Key news highlights Q2 2026 earnings due July 23, 2026, amid fuel cost volatility and travel demand resilience.

LUV presents a cautious opportunity with upside to the consensus target, supported by operational improvements and sector tailwinds, but risks from fuel price swings, execution challenges, and thin margins warrant careful monitoring. The stock's valuation at a P/E of 32.05 appears elevated relative to earnings growth, requiring strong future performance to justify current levels.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.

The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Southwest Airlines Co

Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.

Read more on LUV

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL